William Tse, MD, FACP

Education:

Medical School: Sun Yat Sen University School of Medicine, P. R. China
Residency: 1) Sun Yat Sen University Cancer Center: Thoracic Surgical Oncology
Residency: 2) North Shore-Long Island Jewish Medical Center: Internal Medicine and Clinical Pathology
Fellowship: Fred Hutchinson Cancer Research Center/University of Washington School of Medicine: Medical Oncology   and Bone Marrow Transplantation

Curriculum Vitae

Current Positions:

Marion F. Beard Endowed Chair in Hematology
Chief, Division of Blood and Bone Marrow Transplantation

Contact Information:

Academic Office:  502-562-3228
Patient referral: 502-562-3301

Clinical Focus and Research:

Dr. William Tse is Professor of Medicine and attending physician at James Graham Brown Cancer Center, University of Louisville School of Medicine.  Dr. Tse received his medical degree from Sun Yat-Sen University School of Medicine, Guangzhou, P. R. China. He completed his internal medicine training at Long Island Jewish Medical Center/Albert Einstein College of Medicine and Medical Oncology/Bone Marrow Transplantation Fellowship at The Fred Hutchinson Cancer Research Center/University of Washington School of Medicine.  Along with his clinical training, he received his laboratory research training at the Ontario Cancer Institute/Princess Margaret Hospital and The Hospital for Sick Children, University of Toronto, Toronto, Canada.

Dr. Tse is focused on clinical and translational cancer research for hematopoietic malignancies including pre-clinical models for developmental therapeutics, cancer biology, and cancer cell signaling network profiles. Tse lab translational research is focused on the paralleled signaling pathway activation in cancer and leukemic stem cells. Dr. Tse identified a novel co-factor, AF1q, interacts with T-cell-factor (TCF) associated transcriptional machinery that activates the stemness related Wnt signaling pathway and turns it into autonomously deregulated. At the meantime, the AF1q co-factor also simultaneously activates the Notch and PDGF/Stat3 signaling pathways that are also associated with cancer and leukemic stem cells behaviors. Tse’s work demonstrates an innovative multi-targeted therapeutic approach for a subgroup of leukemia and solid cancer patients that have the AF1q-centered aberrant signaling pathways.

He received the National Cancer Institute of Canada’s Terry Fox Physician Scientist Fellowship Award, the Association of Specialty Professors (ASP) T. Franklin Williams Scholar Award, and the ASCO Career Development Award.  Other honors that he has received include the Dr. Irwin Katzka Memorial Award for Humanitarianism and Resident Teacher of the Year from Long Island Jewish Medical Center, Albert Einstein College of Medicine at Long Island Campus.  He also actively serves on multiple journals’ editorial boards, including PLoS One, Journal of Hematology and Oncology, American Journal of Stem Cell, American Journal of Blood Research, and Experimental Hematology and Oncology.

Literature Cited:

  1. Tse W, Zhu W, Chen HS and Cohen A.: A novel gene, AF1q, fused to MLL in t (1; 11) (q21; q23), is specifically expressed in leukemic and immature hematopoietic cells. Blood 85:650-656, 1995
  2. Tse W, Meshinchi S, Todd Alonzo, Appelbaum FR, and Radich JP: Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia. Blood 104:3058-3063,2004
  3. Tse W, Deeg JH, Stirewalt DL, Appelbaum FR, Radich JP, Gooley T: Increased AF1q gene expression in high-risk myelodysplastic syndrome. British Journal of Hematology 128 (2):218-220; 2005
  4. Strunk CJ, Platzbecker U, Thiede C, Schaich M, Illmer T, Kang Z, Leahy P,Li C, Xie XY, Laughlin MJ, Lazarus HM, Gerson SL, Bunting KD,Ehninger G, Tse W.: Elevated AF1q Expression is a Poor Prognostic Marker for Adult Acute Myeloid Leukemia Patients with Normal Cytogenetics.  Am J Hematol. 2009 May;84 (5):308-9.
  5. 31. Xiong Y, Li Z, Ji M, Park J, Tan AC, Bemis L, Bunting KD & Tse W: Mir-29b   regulates expression of AF1q, an MLL fusion partner, and low miR-29b expression associates with adverse cytogenetics and poor overall survival in AML.  Br J Haematol. 2011 Jun;153(6):753-757.

PubMed Information